Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | MGAM | O43451 | 1/20 | 0.48 |
| ▸ | SI | P14410 | 1/20 | 0.48 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 8/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11783978 | 0.92 | KDM4E (0.59) | CYP1A2KDM4EMAPK1HIF1ACYP3A4 | |
| SCHEMBL48439 | 0.88 | GAA (0.52) | CYP1A2KDM4EMAPK1HIF1AALDH1A1 | |
| SCHEMBL5812715 | 0.85 | DGKA (0.50) | KDM4EMAPK1HIF1ASMN1; SMN2PAOX | |
| SCHEMBL25349245 | 0.84 | CYP1A2 (0.53) | CYP1A2KDM4ECYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL17891818 | 0.82 | CYP1A2 (0.57) | CYP1A2KDM4ECYP3A4CYP2C19ALDH1A1 | |
| Hydrochloric Acid SCHEMBL4415432 | 0.82 | CYP1A2 (0.52) | CYP1A2KDM4ECYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL31126988 | 0.82 | EPHX1 (0.55) | CYP1A2KDM4ECYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL4692794 | 0.82 | CYP1A2 (0.52) | CYP1A2KDM4ECYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL27780836 | 0.82 | CYP1A2 (0.47) | CYP1A2KDM4ECYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL407248 | 0.81 | TSHR (0.61) | KDM4EMAPK1HIF1AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060251597-A1 | ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE | YU RUEY J | 2006-11-09 | — | — | US | claimed |
| EP-0973768-B1 | AZOLE COMPOUNDS, THEIR PRODUCTION AND THEIR USE | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-07-09 | — | — | EP | claimed |
| EP-0973768-A1 | AZOLE COMPOUNDS, THEIR PRODUCTION AND THEIR USE | Takeda Chemical Industries, Ltd. (JP) | 2000-01-26 | — | — | EP | claimed |
| WO-1998043970-A1 | AZOLE COMPOUNDS, THEIR PRODUCTION AND THEIR USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-10-08 | — | — | WO | claimed |
| US-20210238124-A1 | ACETYLATED PRODRUGS FOR DELIVERY ACROSS THE BLOOD-BRAIN BARRIER | THE GENERAL HOSPITAL CORPORATION (US) | 2021-08-05 | — | — | US | disclosed |
| WO-2019204808-A1 | ACETYLATED PRODRUGS FOR DELIVERY ACROSS THE BLOOD-BRAIN BARRIER | THE GENERAL HOSPITAL CORPORATION (US) | 2019-10-24 | — | — | WO | disclosed |
| US-8524906-B2 | Tetrahydrothiazolopyridine inhibitors of phosphatidylinositol 3-kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-03 | — | — | US | disclosed |
| US-20130172349-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | NOVARTIS AG (CH) | 2013-07-04 | — | — | US | disclosed |
| US-20130172349-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | NOVARTIS AG (CH) | 2013-07-04 | — | — | US | disclosed |
| US-8404684-B2 | Inhibitors of phosphatidylinositol 3-kinase | NOVARTIS AG (CH) | 2013-03-26 | — | — | US | disclosed |
| US-8404684-B2 | Inhibitors of phosphatidylinositol 3-kinase | NOVARTIS AG (CH) | 2013-03-26 | — | — | US | disclosed |
| US-8198456-B2 | e.g. 1,4-dihydro-4-(1H-indazol-5-yl)-2,6-dimethyl-3,5-pyridinedicarbonitrile; c-Met tyrosine kinase inhibitor; antitumor agent; lung, liver, gastric and breast solid tumors; pancreatic cancer, glioma, and hepatocellular carcinoma | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| US-20060251597-A1 | ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE | YU RUEY J | 2006-11-09 | — | — | US | disclosed |
| US-20050085508-A1 | Novel 4-(2-furoyl) aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2005-04-21 | — | — | US | disclosed |
| EP-1443046-A1 | NOVEL 4-(2FUROYL)AMINOPIPERIDINES, INTERMEDIATES IN SYNTHESIZING THE SAME, PROCESS FOR PRODUCING THE SAME AND MEDICINAL USE OF THE SAME | Kyorin Pharmaceutical Co., Ltd. (JP) | 2004-08-04 | — | — | EP | disclosed |
| US-6583164-B1 | Lyophilized imidazole-1-yl or 1,2,4-triazole-1-yl quaternized with a alklycarbonyloxy alkyl group eliminated in vivo; a saccharide; 4-acetoxymethyl-1-(3-(2-oxo-3-(4-(1H-tetrazol-yl) phenyl)-1-imidazolydinyl)butyl)-1H-1,2,4-triazolium chloride | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-06-24 | — | — | US | disclosed |
| US-6407129-B1 | INJECTABLE QUATERNIZED SALT FUNGICIDES; WATER SOLUBILITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-06-18 | — | — | US | disclosed |
| EP-1120116-A1 | ANTIMYCOTIC DRUG COMPOSITION | Takeda Chemical Industries, Ltd. (JP) | 2001-08-01 | — | — | EP | disclosed |
| EP-0973768-A1 | AZOLE COMPOUNDS, THEIR PRODUCTION AND THEIR USE | Takeda Chemical Industries, Ltd. (JP) | 2000-01-26 | — | — | EP | disclosed |
| WO-1998043970-A1 | AZOLE COMPOUNDS, THEIR PRODUCTION AND THEIR USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238124-A1 | ACETYLATED PRODRUGS FOR DELIVERY ACROSS THE BLOOD-BRAIN BARRIER | AADAC, ACAT2, AANAT | CYP1A2 414/4885KDM4E 1085/4885MAPK1 4146/4885 |
| US-20050085508-A1 | Novel 4-(2-furoyl) aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same | OPRM1, OPRD1, HRH4 | CYP1A2 314/4885KDM4E 1590/4885MAPK1 2707/4885 |
| US-20130172349-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CA, PIK3CD, PIP4K2C | CYP1A2 2852/4885KDM4E 1819/4885MAPK1 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.